|Articles|September 1, 2008
- The Application Notebook-09-01-2008
- Volume 0
- Issue 0
Analysis of Voglibose in Pharmaceutical Formulations by HPLC with Post-Column Derivatization
Voglibose is an Alpha-Glucosidase inhibitor widely used for the treatment of diabetes. Alpha-glucosidase inhibitors are agents that delay the glucose absorption at the intestinal level and thereby prevent sudden surge of glucose after a meal. Voglibose is the safest and most effective drug of its class.
Maria Ofitserova Ph.D., Sareeta Nerkar, Ph. D., and Michael Pickering Ph.D., Pickering Laboratories
Voglibose is an Alpha-Glucosidase inhibitor widely used for the treatment of diabetes. Alpha-glucosidase inhibitors are agents that delay the glucose absorption at the intestinal level and thereby prevent sudden surge of glucose after a meal. Voglibose is the safest and most effective drug of its class.
Table I: Repeatability studies for different concentration levels
Since Voglibose has no UV chromophore, post-column deriv-atization is employed to produce a fluorescent derivative.
Figure 1
This abstract describes a very sensitive and robust analytical method for the analysis of Voglibose in pharmaceutical tablets. Simple sample preparation and fast analysis time allow for using this method in high throughput environments.
Figure 2
Pickering Laboratories, Inc.
1280 Space Park Way
Mountain View, California 94043
Tel (650) 694-6700
Email:
Articles in this issue
over 17 years ago
Analysis of Melamine and Cyanuric Acid in Food Matrices by LC–MS-MSover 17 years ago
From the Publisher: Timing is Everythingover 17 years ago
Techniques for Reducing Purge-and-Trap Cycle Times in VOC AnalysisNewsletter
Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.
Related Content
Trending on LCGC International
1
Decoding Sweet Potato Drought Resilience: Metabolomic Evidence from UPLC-MS Profiling
2
Navigating Adverse Reactions in GLP-1 Treatment
3
Toward Safer Diabetes Devices: GC–MS Detection of Allergens in Sensors, Pumps, and Infusion Sets
4
Shifting GLP-1 Receptor Agonists from Proteins to Small Molecules
5
